Nine novel germline gene variants in the RET proto-oncogene indentified in twelve unrelated cases

Journal of Molecular Diagnostics

Volumn 7, Issue 2, 2005, Pages 283-288

  Ahmed, Syed A ^a   Snow Bailey, Karen ^b   Highsmith, W Edward ^a   Sun, Weimin ^c   Fenwick, Raymond G ^c   Mao, Rong ^d  

^a MAYO CLINIC   (United States)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^d ARUP LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ARGININE; ASPARTIC ACID; CYSTEINE; DNA; GLUTAMINE; GLYCINE; GUANINE; HISTAMINE; LEUCINE; LYSINE; ONCOPROTEIN; PROTEIN RET; TYROSINE; VALINE;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DNA SEQUENCE; EXON; GENE ACTIVITY; GENE DELETION; GENE IDENTIFICATION; GENE MUTATION; GENE SEGREGATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GERM LINE; GOITER; HUMAN; HUMAN CELL; MEDICAL ASSESSMENT; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHEOCHROMOCYTOMA; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA;

ANIMALIA;

EID: 18744374884     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-1578(10)60556-9     Document Type: Article

References (29)

1. Easton DF, Ponder MA, Cummings T, Gagel RF, Hansen HH, Reichlin S, Tashjian AH Jr, Telenius-Berg M, Ponder BA: The clinical and screening age-at-onset distribution for the MEN-2 syndrome. Am J Hum Genet 1989, 44:208-215
2. Ponder BAJ, Smith D: The MEN-2 syndromes and the role of the RET proto-oncogene. Adv Cancer Res 1996, 70:179-222
3. Hansford JR, Mulligan LM: Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 2000, 37:817-827
4. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenins H, Tunnacliffe A, Ponder. BM: Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2. Nature 1993, 363:458-460
5. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H, Hartmut NH, Thibodeau SN, Ponder. BA: Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994, 6:70-74
6. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJ, Gagel RF, Takai SI, Noll WW, Fink M: Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 1995, 238:343-346
7. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA Jr: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993, 2:851-856
8. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GF, Jackson CE, Tunnacliffe A, Ponder BA: Point mutations within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumors. Hum Mol Genet 1994, 2:237-241
9. Takahashi M: Oncogenic activation of the RET proto-oncogene in thyroid cancer. Crit Rev Oncog 1995, 6:35-46
10. Takahashi M, Asai N, Iwashita T, Murakami H, Ito S: Molecular mechanism of development of multiple endocrine neoplasia 2 by RET mutations. J Intern Med 1998, 243:509-513
11. Kwok BJ, Gardner E, Warner JP, Ponder BA, Mulligan LM: Structure analysis of the human Ret proto-oncogene using exon trapping. Oncogene 1993, 8:2575-2582
12. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, Cooper DN: Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003, 21:577-581
13. Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M: RET mutations in exons 13 and 14 of FMTC patients. Oncogene 1995, 10:2415-2419
14. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD, Ponder BA: A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995, 10:509-513
15. Smith DP, Houghton C, Ponder BA: Germline mutations of RET codon 883 in two cases of de novo MEN2B. Oncogene 1997, 15:1213-1217
16. Boccia LM, Green JS, Joyce C, Eng C, Taylor SA, Mulligan LM: Mutation of RET codon 768 is associated with the FMTC phenotype. Clin Genet 1997, 51:81-85
17. Feldman GL, Edmonds MW, Ainsworth PJ, Schuffenecker I, Lenoir GM, Saxe AW, Talpos GB, Roberson J, Petrucelli N, Jackson CE: Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG→ATG) mutation. Surgery 2000, 128:93-98
18. Frohnauer MK, Decker RA: Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated? Surgery 2000, 128:1052-1057
19. Eng C, Mulligan LM: Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndrome, related sporadic tumors, and Hirschsprung disease. Hum Mutat 1997, 9:97-109
20. Borrego S, Saez ME, Ruiz A, Gimm O, Lopez-Alonso M, Antinolo G, Eng C: Specific polymorphisms in the RET proto-oncogene are overrepresented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. J Med Genet 1999, 36:771-774
21. Heshmati HM, Gharib H, Khosla S, Abu-Lebdeh HS, Lindor N, Thibodeau SN: Genetic testing in medullar thyroid carcinoma syndromes: mutation types and clinical significance. Mayo Clin Proc 1997, 72:430-436
22. Chiefari E, Russo D, Giuffrida D, Zampa GA, Meringolo D, Arturi F, Chiodini I, Brianchi D, Attard M, Trischitta V, Bruce R, Giannasio P, Pontecorvi A, Filetti S: Analysis of RET proto-oncogene abnormalities in patients with MEN2A, MEN2B, familial or sporadic medullary thyroid carcinoma. J Endocrinol Invest 1998, 21:358-364
23. Eng C: RET proto-oncogene in the development of human cancer. J Clin Oncol 1999, 17:380-393
24. Auricchio A, Griseri P, Carpentieri ML, Betsos N, Staiano A, Tozzi A, Bocciardi M, Thompson H, Ballabio A, Ceccherini I: Double heterozygosity for a RET substitution interfering with Splicing and an EDNRB missense mutation in Hirschsprung disease. Am J Hum Genet 1999, 64:1216-1221
25. Miyauchi A, Futami H, Hai N, Yokozawa T, Kuma K, Aoki N, Kosugi S, Sugano K, Yamaguchi K: Two germline missense mutations at codons 804 and 806 of the RET proto- oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res 1999, 90:1-5
26. Bartsch DK, Hasse C, Schug C, Barth P, Rothmund M, Hoppner W: A RET double mutation in the germline of a kindred with FMTC. Exp Clin Endocrinol Diabetes 2000, 108:128-132
27. Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham G, van Veen JM, van Gils AP, de Wit MJ, Zewald RA, Berends MJ, Beemer FA, Browers-Smalbreak RJ, van Amstal HK, van Vroonhoven J, Vroom TM: Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994, 331:828-835
28. Kitamura Y, Goodfellow PJ, Shimizu K, Nagahama M, Ito K, Kitagawa W, Akasu H, Takami H, Tanaka S, Wells SA Jr: Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC. Oncogene 1997, 14:3103-3106
29. Hoppner W, Ritter MM: A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. Hum Mol Genet 1997, 6:587-590